{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:42:12Z","timestamp":1790707332692,"version":"4.1.0"},"reference-count":29,"publisher":"BMJ","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1136\/thoraxjnl-2012-202744","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T20:54:45Z","timestamp":1364504085000},"page":"738-745","source":"Crossref","is-referenced-by-count":115,"title":["Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial"],"prefix":"10.1136","volume":"68","author":[{"given":"William","family":"MacNee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieuan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"De Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa F","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,3,28]]},"reference":[{"key":"key-10.1136\/thoraxjnl-2012-202744-1","volume-title":"Managing chronic obstructive pulmonary disease","author":"Barnes","year":"1999"},{"key":"key-10.1136\/thoraxjnl-2012-202744-2","unstructured":"World Health Statistics. 2008. http:\/\/www.who.int\/whosis\/whostat\/EN_WHS08_Full.pdf (accessed 12 Mar 2013)."},{"key":"key-10.1136\/thoraxjnl-2012-202744-3","unstructured":"The global burden of disease. 2004 update. http:\/\/www.who.int\/healthinfo\/global_burden_disease\/2004_report_update\/en\/index.html (accessed 12 Mar 2013)."},{"key":"key-10.1136\/thoraxjnl-2012-202744-4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0165-6147(98)01245-0","article-title":"Chronic obstructive pulmonary disease: new opportunities for drug development","volume":"19","author":"Barnes","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"key-10.1136\/thoraxjnl-2012-202744-5","doi-asserted-by":"crossref","first-page":"L895","DOI":"10.1152\/ajplung.2000.279.5.L895","article-title":"SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9 and fibrosis in lung","volume":"279","author":"Underwood","year":"2000","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"key-10.1136\/thoraxjnl-2012-202744-6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1183\/09031936.00036707","article-title":"Increased activation of p38 MAPK in COPD","volume":"31","author":"Renda","year":"2008","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2012-202744-7","article-title":"Do p38 alpha inhibitors represent a potential anti-inflammatory treatment for COPD? European Respiratory Society Lung Inflammation Conference","author":"Kilty"},{"key":"key-10.1136\/thoraxjnl-2012-202744-8","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1021\/bi900655f","article-title":"Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804","volume":"48","author":"Xing","year":"2009","journal-title":"Biochemistry"},{"key":"key-10.1136\/thoraxjnl-2012-202744-9","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1124\/jpet.109.158329","article-title":"Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation","volume":"331","author":"Hope","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.1136\/thoraxjnl-2012-202744-10","unstructured":"GOLD guidelines. (2010 update). http:\/\/www.goldcopd.org\/uploads\/users\/files\/GOLDReport_April112011.pdf (accessed 12 Mar 2013)."},{"issue":"Suppl 54","key":"key-10.1136\/thoraxjnl-2012-202744-11","first-page":"P4000","article-title":"A randomized, placebo controlled trial of 6 weeks\u2019 treatment with a novel oral p38 inhibitor in patients with COPD","volume":"36","author":"MacNee","year":"2010","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2012-202744-12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnoea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"key-10.1136\/thoraxjnl-2012-202744-13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/COPD-200050666","article-title":"The MCID of the transition dyspnoea index is a total score of one unit","volume":"2","author":"Mahler","year":"2005","journal-title":"COPD"},{"key":"key-10.1136\/thoraxjnl-2012-202744-14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"ATS\/ERS Task Force: standardisation of lung function testing. Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2012-202744-15","unstructured":"FDA. Guidance for the use of Bayesian statistics in medical device clinical trials. 2010. http:\/\/www.fda.gov\/medicaldevices\/deviceregulationandguidance\/guidancedocuments\/ucm071072.htm (accessed 12 Mar 2013)."},{"key":"key-10.1136\/thoraxjnl-2012-202744-16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pst.198","article-title":"Implementation of a Bayesian adaptive design in a proof of concept study","volume":"5","author":"Smith","year":"2006","journal-title":"Pharm Stat"},{"key":"key-10.1136\/thoraxjnl-2012-202744-17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"M2\u2013127 and M2\u2013128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"key-10.1136\/thoraxjnl-2012-202744-18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS\u2014a Bayesian modelling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"key":"key-10.1136\/thoraxjnl-2012-202744-19","doi-asserted-by":"crossref","DOI":"10.1002\/0470023589","volume-title":"Applied mixed models in medicine","author":"Brown","year":"2006","edition":"2"},{"key":"key-10.1136\/thoraxjnl-2012-202744-20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"American Thoracic Society, European Respiratory Society Task Force on Outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2012-202744-21","first-page":"416","article-title":"An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease","volume":"52","author":"Lomas","year":"2012","journal-title":"J Clin Phamacol"},{"key":"key-10.1136\/thoraxjnl-2012-202744-22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1183\/09031936.00098307","article-title":"Methodological issues in therapeutic trials of COPD","volume":"31","author":"Suissa","year":"2008","journal-title":"Eur Respir J"},{"key":"key-10.1136\/thoraxjnl-2012-202744-23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250\u2005\u00b5g)\/salmeterol (50\u2005\u00b5g) combined in the Diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"key":"key-10.1136\/thoraxjnl-2012-202744-24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(05)67100-0","article-title":"Roflumilast\u2014an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial","volume":"366","author":"Rabe","year":"2005","journal-title":"Lancet"},{"key":"key-10.1136\/thoraxjnl-2012-202744-25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"key":"key-10.1136\/thoraxjnl-2012-202744-26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Trial of Inhaled Steroids and Long-acting beta2 Agonists Study Group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"key-10.1136\/thoraxjnl-2012-202744-27","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.1136\/thoraxjnl-2012-202744-28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/art.24266","article-title":"Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis","volume":"60","author":"Cohen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key-10.1136\/thoraxjnl-2012-202744-29","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2012-202744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:15:35Z","timestamp":1601057735000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2012-202744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,28]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,7,9]]},"published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1136\/thoraxjnl-2012-202744"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2012-202744","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717995534.793475842","asserted-by":"object"}]},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,28]]}}}